Overview

  • Product nameAnti-Tau antibody [Tau 12]
    See all Tau primary antibodies
  • Description
    Mouse monoclonal [Tau 12] to Tau
  • Tested applicationsIHC-P, WB, ELISAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human Tau aa 6-18.

  • Epitopeab74137 is specific for an epitope that lies between amino acids 9-18 of human Tau.
  • General notesDo not store antibody diluted below 50 ug/mL in the absence of protein (i.e.: add 2% bovine serum albumin).

Properties

Applications

Our Abpromise guarantee covers the use of ab74137 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent dilution.
WB Use at an assay dependent dilution. Predicted molecular weight: 79 kDa.
ELISA Use at an assay dependent dilution.

Target

  • FunctionPromotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
  • Tissue specificityExpressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
  • Involvement in diseaseNote=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU).
    Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
    Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
    Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
    Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104, 260540]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
  • Sequence similaritiesContains 4 Tau/MAP repeats.
  • Developmental stageFour-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
  • DomainThe tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
  • Post-translational
    modifications
    Phosphorylation at serine and threonine residues in S-P or T-P motifs by proline-directed protein kinases (PDPK: CDK1, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis.
    Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
    Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
  • Cellular localizationCytoplasm > cytosol. Cell membrane. Cytoplasm > cytoskeleton. Cell projection > axon. Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
  • Information by UniProt
  • Database links
  • FormThere are 9 isoforms produced by alternative splicing.
  • Alternative names
    • AI413597 antibody
    • AW045860 antibody
    • DDPAC antibody
    • Disinhibition dementia parkinsonism amyotrophy complex antibody
    • FLJ31424 antibody
    • FTDP 17 antibody
    • FTDP17 antibody
    • G Protein beta 1 gamma 2 subunit interacting factor 1 antibody
    • G protein beta1/gamma2 subunit interacting factor 1 antibody
    • MAPT antibody
    • MAPTL antibody
    • MGC134287 antibody
    • MGC138549 antibody
    • MGC156663 antibody
    • Microtubule associated protein tau antibody
    • Microtubule associated protein tau isoform 4 antibody
    • Microtubule-associated protein tau antibody
    • MSTD antibody
    • MTAPT antibody
    • MTBT 1 antibody
    • MTBT 2 antibody
    • MTBT1 antibody
    • MTBT2 antibody
    • Neurofibrillary tangle protein antibody
    • Paired helical filament tau antibody
    • Paired helical filament-tau antibody
    • PHF tau antibody
    • PHF-tau antibody
    • PPND antibody
    • pTau antibody
    • RNPTAU antibody
    • TAU antibody
    • TAU_HUMAN antibody
    • Tauopathy and respiratory failure, included antibody
    see all

Anti-Tau antibody [Tau 12] images

  • Lanes 1 & 4 : Anti-Tau antibody [Tau 12] (ab74137) at 1/5000 dilution
    Lanes 2 & 5 : Anti-Tau antibody [HT-7] at 1/500 dilution
    Lanes 3 & 6 : Anti-Tau polyclonal antibody

    Lane 1 : Human Tau-GFP over-expression HeLa cell lysate
    Lane 2 : Human Tau-GFP over-expression HeLa cell lysate
    Lane 3 : Human Tau-GFP over-expression HeLa cell lysate
    Lane 4 : Empty GFP-vector HeLa cell lysate
    Lane 5 : Empty GFP-vector HeLa cell lysate
    Lane 6 : Empty GFP-vector HeLa cell lysate

    Secondary
    Peroxidase-conjugated IgG

    Predicted band size : 79 kDa

    Image from Plouffe V et al., PLoS One. 2012;7(5):e36873. Epub 2012 May 15. Fig 1.; doi:10.1371/journal.pone.0036873; May 15, 2012, PLoS ONE 7(5): e36873.

References for Anti-Tau antibody [Tau 12] (ab74137)

This product has been referenced in:
  • Petry FR  et al. Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. PLoS One 9:e94251 (2014). WB ; Mouse . Read more (PubMed: 24788298) »
  • Plouffe V  et al. Hyperphosphorylation and cleavage at D421 enhance tau secretion. PLoS One 7:e36873 (2012). WB . Read more (PubMed: 22615831) »

See all 2 Publications for this product

Product Wall

Thank you for contacting us and for your interest in our products.

I am sorry to confirm that as far as we are aware, ab22261 and ab74137 have not been tested with samples from mouse or rat. All tested species covered by our 6 month guarante...

Read More

Thank you for your inquiry. Unfortunately, we do not offer custom conjugated antibodies. If you would like to conjugate these antibodies yourself I can recommend to use one of our EasyLink antibody conjugation kits. Not only bio...

Read More

Thank you for your enquiry and your interest in our products. Currently, we can't offer custom-made biotin conjugation service. However, we have another primary antibody in our catalogue (ab12357) which is already conjugated to biotin and we se...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"